Celcuity Inc

CELC remains in a sustained Stage 4 decline with sequential lower highs and lower lows under declining EMAs. While the medium-term bias is bearish, near-term price is extended and oversold without a clear exhaustion signal. Under a Speculative approach, high selectivity demands patience; execution is deferred. Plan to Trim into any relief rally into the 9/20 EMA and 50 DMA resistance confluence for higher-probability entries.

• ↑Phase III Victoria I trial reported 9.3-month median PFS for gadotelicib.
• ↑FDA PDUFA date set for July 17, 2026; management sees no delay risk.
• ↓Q1 2026 net loss rose to $52.8M vs $37M last year.